Moreover, soluble FADD appeared as a biomarker of structural severity in early RA-suffering patients from the ESPOIR cohort, since baseline serum FADD levels were associated with structural progression (characterized by joint erosion and joint space narrowing) within the first 2 years of follow-up. Here, FADD is linked to rheumatoid arthritis.